Clinical Trial Information A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohns disease Protocol Number: 11254 Status: Open Treatment Type: Treatment Phase: III NCT ID: NCT03926130 Scope Information Disease Site(s): Other
